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ComParative Cost-effeCtiveness of BeCaPlermin gel on wounD 
healing in Patients with DiaBetiC foot ulCer: Changes in wounD 
surfaCe area
Waycaster C., Gilligan A.M.
Smith & Nephew Biotherapeutics, Fort Worth, TX, USA
Objectives: Determine the cost-effectiveness of becaplermin gel for the treatment 
of diabetic foot ulcers (DFU) relative to good wound care (GWC) alone. MethOds: 
Wound surface area (WSA) reduction rates were used to predict the expected costs 
and outcomes of wound healing for becaplermin versus GWC cohorts over a 1-year 
time horizon. Changes in WSA were taken from the Phase 3 pivotal trials. The out-
comes of the analysis include the average percent reduction of baseline WSA, the 
direct costs of DFU therapy and the cost per centimeter squared of WSA reduction. 
The costs for becaplermin gel and DFU patient evaluation and management were 
derived from standard cost references. Becaplermin utilization was calculated using 
the manufacturer’s recommended dosing algorithm. The economic perspective was 
that of the payer. Costs are reported in 2013 US dollars. Results: The average WSA 
at baseline was 2.2 centimeters squared. At 20 weeks in the clinical study the beca-
plermin group demonstrated a statistically higher probability of complete wound 
closure compared to the GWC group (p= 0.015) at 50% versus 35%, respectively. Given 
the reported WSA reduction rates, becaplermin treated DFU were expected to close 
100% at 27 weeks while the GWC group reached an expected 88% reduction in WSA 
at 52 weeks. When costs were compared by wound closure rates, the cost per 1 
centimeter reduction in WSA was $1,285 in the becaplermin group compared to 
$3,446 in the GWC group. The total expected direct cost of DFU care across the 
1-year time horizon was estimated at $6,702 in the GWC group compared to $2,827 
in the becaplermin group. cOnclusiOns: DFU patients treated with becaplermin 
experienced better clinical outcomes than those treated with GWC alone. As a result 
of the improved outcomes becaplermin demonstrated economic dominance over 
GWC providing better outcomes at a lower direct cost.
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ComParative Cost effeCtiveness of metformin-BaseD oral 
hyPoglyCemiC theraPy in PoPulation-BaseD DataBase
Ou H.T., Chen M.C., Chen Y.T.
National Cheng Kung University, Tainan, Taiwan
Objectives: Although metformin remained the mainstay of oral hypoglycemic 
agent (OHA), patients receiving combined OHAs significantly increased. We aimed 
to differentiate real-world effectiveness and economic benefit of metformin-based 
OHAs, from the perspective of Taiwan’s National Health Insurance (NHI). MethOds: 
The NHI Research Database 1999 – 2012 was used, which was derived from the 
claims of Taiwan NHI, a mandatory-enrollment and single-payment system cre-
ated in 1995, covering over 99% of the population. Four metformin-based cohorts 
were extracted: one reference group was metformin plus sulphonylureas (Met-SU), 
and three comparison groups were metformin plus acarbose (Met-ACA), metformin 
plus thiazolidinediones (Met-TZD), and metformin plus meglitidine. By using pro-
pensity scores, each comparison cohort subject was 1:1 matched to the reference 
subject on demographics and comorbidity. The effectiveness outcome of interest 
was diabetes associated cardiovascular disease (CVD) complication risk. Only direct 
medical costs were included (expressed in 2012 U.S. dollars). A Markov model was 
applied to project lifetime effectiveness and economic outcomes, discounted at 
3% per annum. Bootstrapping technique was used for assessing uncertainty in 
cost-effectiveness analyses. Results: The age-gender weighted average lifetime 
costs was $94,112.5, of which 61% was attributed to diabetic complications and the 
managing CVD accounted for 67% of total complication costs. The estimated CVD 
risk was 34%, with the highest in Met-SU and the lowest in Met-TZD (40% vs. 31%, 
p< .05). After a 10 year follow-up, average expenditure in Met-TZD was highest, due 
to higher drug acquisition price of TZD. However, over a lifetime, Met-ACA had the 
highest spending, most attributed to managing diabetic complications. The sensitiv-
ity analysis consistently demonstrated the cost-effectiveness of Met-TZD vs. other 
metformin-based therapies. cOnclusiOns: Over a lifetime, Met-TZD combina-
tion was the least expensive and most effective in lowering CVD risk. The results 
would inform clinical selection of “add-on” therapy in patients with inadequately 
controlled by metformin.
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in sPain
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Objectives: Metformin forms the first-line therapy for patients with type 2 dia-
betes, but the majority require treatment intensification at some stage due to the 
progressive nature of the disease. The 1860-LIRA-DPP4 trial showed that, at 52 weeks, 
liraglutide exhibited greater improvements compared with sitagliptin in HbA1c, 
blood pressure, serum lipids and BMI in patients with diabetes inadequately con-
trolled on metformin monotherapy. This study compared the long-term clinical 
and cost implications associated with liraglutide and sitagliptin for subjects with 
type 2 diabetes in Spain. MethOds: Data were taken from the 1860-LIRA-DPP4 trial 
randomized, controlled trial at 52 weeks, in which adults with type 2 diabetes were 
randomly allocated to receive either 1.8mg liraglutide or 100mg sitagliptin daily in 
addition to metformin. Long-term (patient lifetime) projections of clinical outcomes 
and direct costs (2012 EUR) were made using a published and validated model of 
type 2 diabetes. Outcomes were discounted at 3% annually. Sensitivity analyses 
were performed and support the findings. Results: Liraglutide was associated 
with improved clinical outcomes over sitagliptin in terms of life expectancy (14.24 
versus 13.87 years) and quality adjusted life-expectancy (9.24 versus 8.84 quality-
adjusted life years [QALYs]). Improved clinical outcomes were driven by improved 
of wound healing and amputation rates for becaplermin and non-becaplermin 
DFU cohorts over a 1-year time period. Outcome data used in the analysis were 
derived from a propensity score matched cohort of 24,898 subjects with DFU from 
the Curative Health Services database from 1998-2004 who were followed for 20 
weeks. Primary outcomes of interest were ulcer-free weeks and rates of amputa-
tion. Costs for amputation and becaplermin gel*were derived from standard cost 
references and medical supply wholesalers. Total weekly costs per episode of DFU 
care were estimated from a large retrospective claims database. Transition probabili-
ties for healing and amputation were derived from the aforementioned propensity 
score matched cohorts. Ulcer recurrence was estimated from the medical literature. 
Utilization for becaplermin was calculated using the manufacturer’s recommended 
dosing algorithm. The economic perspective taken was that of the payer. Costs are 
reported in 2013 US dollars. Results: Overall, 2,394 (9.6%) received becaplermin. 
Of those who received becaplermin, 33.5% healed at 20 weeks compared to 26.5% 
who did not receive becaplermin (p< 0.0001). In addition, the percent of patients 
requiring amputation were significantly (p< 0.0001) lower in the becaplermin cohort 
(4.9% versus 6.4%, respectively). Patients treated with becaplermin had substantially 
higher ulcer-free weeks compared to non-becaplermin patients (16.1 versus 12.5 
weeks, respectively). Expected annual direct costs for DFU were $20,885 for becapler-
min and $23,506 for non-becaplermin. cOnclusiOns: Becaplermin was economi-
cally dominant over standard therapy, providing better outcomes at a lower cost in 
patients with DFU. In addition, becaplermin is more effective in wound healing and 
preventing amputation, thereby decreasing long-term costs for DFU. *Regranex®, 
Smith & Nephew Biotherapeutics, Fort Worth, Texas
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Cost-effeCtiveness of small intestinal suBmuCosa extraCellular 
matrix on wounD Closure in Patients with DiaBetiC foot ulCer
Gilligan A.M., Waycaster C.
Smith & Nephew Biotherapeutics, Fort Worth, TX, USA
Objectives: Determine the cost-effectiveness of small intestinal submucosa 
extracellular matrix (SISEM)* relative to human fibroblast-derived dermal sub-
stitute (HF-DDS)†on wound closure for the treatment of diabetic foot ulcers 
(DFUs). MethOds: A 2-stage Markov model was used to predict the expected costs 
and outcomes of wound closure for SISEM and HF-DDS. Outcome data used in the 
analysis were taken from a 12-week randomized clinical trial that directly com-
pared SISEM and HF-DDS. Twenty-six patients completed the study; 13 for SISEM 
and 13 for HF-DDS. The primary outcome of interest was ulcer-free days. Transition 
probabilities for the Markov states were estimated from the clinical trial. Resource 
utilization was based on the treatment regimen used in the clinical trial. Costs were 
derived from standard cost references and medical supply wholesalers. The eco-
nomic perspective taken was that of the payer. No cost discounting was performed 
due to the short duration of the study. Results: Ten wounds closed in the SISEM 
group (77%), with an average time to closure of 36 days, while 11 wounds closed 
in the HF-DDS group (85%), with an average closure time of 41 days. No significant 
difference was found in the time to closure or in the percentage of wound closure 
between the two groups (p= 0.73). Expected direct costs per patient for DFU were 
$2,949 for SISEM and $5,282 for HF-DDS. Patients treated with HF-DDS incurred 
total treatment costs that were approximately 1.8 times higher than those treated 
with SISEM. The estimated cost per ulcer-free day was more than 1.5 times higher 
HF-DDS vs. SISEM. cOnclusiOns: SISEM yielded similar outcomes at a lower cost 
in patients with DFU. Health care providers should consider SISEM as a cost-saving 
alternative to HF-DDS. *OASIS®, Smith & Nephew Biotherapeutics, Fort Worth, Texas 
†Dermagraft®, Shire Regenerative Medicine Inc., San Diego, California
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aDDing vilDagliPtin to stanDarD Care in Patients with tyPe 2 
DiaBetes in ColomBia- a Cost-effeCtiveness analysis
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Alfonso-Cristancho R.6
1RANDOM Foundation, Bogota, Colombia, 2RANDOM Foundation, Bogota, DC, Colombia, 
3Novartis, Bogota, Colombia, 4Novartis, Colombia, 5Clinicos IPS, 6University of Washington, 
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Objectives: Vildagliptin is a DPP-4 inhibitor available in Colombia for the treat-
ment of diabetes mellitus as monotherapy or in combination with metformin, 
sulfonylureas, or insulin. Our aim was to determine the cost-effectiveness of the 
addition of vildagliptin to metformin, or sulfonylureas for the management of 
type 2 diabetes in Colombia. MethOds: We developed a hybrid decision Markov 
model to simulate the level of glycemic control and the health states associated 
with macrovascular complications (myocardial infarction, disabling stroke, and 
heart failure), nephropathy and death in a hypothetic cohort of patients with type 
2 diabetes. Transition probabilities and utilities were derived from published trials 
and validated with local clinical experts. Costs were calculated based on resource 
use from local clinical guidelines and databases from the Ministry of Health and 
private institutions. The base case was developed based on the demographic char-
acteristics of patients with type 2 diabetes in Colombia with a mean age of 59 
years. The analysis was performed from the payer perspective for a time horizon 
of 20 years. Multivariate sensitivity analysis was performed. Results: Our results 
show that the addition of vildagliptine to metformine yielded an incremental 
effectiveness of 0.83 QALY’s over the 20 years of this cohort when compared to 
metformine alone. The addition of vildagliptine to metformine + glimepiride com-
bination yielded an minor increase in QALY’s of only 0.27. Incremental cost for 
the addition of vildagliptine to metformine was $COP 3,626,000 ($1,900 USD). The 
incremental cost of the addition of vildagliptine to the combination of metform-
ine was $COP 9,713,169 ($5,100 USD). The ICER for the addition of vildagliptine to 
metformine was $COP 4,358,350 ($2,500 USD) and to metformine + glimepiride 
was $ COP 35,697,647 ($18,700 USD). cOnclusiOns: The addition of vildagliptine 
to metformine and metformine+glimepiride is a cost-effective alternative for the 
treatment of diabetes type 2 in Colombia.
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comparators using Swedish-specific data, where available. Direct and indirect costs 
were reported in 2012 Euro [1 Euro (€ ) = 8.91 Swedish Krona] and an annual discount 
rate of 3% was applied on costs and effects. Results: With inclusion of indirect 
costs the cost-effectiveness analyses indicate that in dual therapy when compared 
to sitagliptin as add-on to metformin, canagliflozin appears to dominate sitagliptin 
with average cost savings of 718 € and an average QALY gain of 0.011 and as add-on 
to metformin canagliflozin appears to dominate sulfonylurea with average cost 
savings of 600 € and an average QALY gain of 0.063. As add-on to insulin canagliflo-
zin appears to dominate placebo with an incremental cost saving of 3339 € and an 
incremental QALY of 0.054. In mono therapy canagliflozin is cost-effective compared 
to sulfonylurea with an incremental cost-effectiveness ratio (ICER) of 1838 € per 
QALY. Probabilistic analysis of the four comparisons suggests a likelihood of above 
50% of canagliflozin being cost-effective. Sensitivity analyses show that canagliflo-
zin remains cost-effective when indirect costs were not included. cOnclusiOns: 
Canagliflozin 100 mg and 300 mg (80/20 dose split) appears to be a cost-effective 
alternative to sitagliptin and glimepiride in dual therapy as add-on to metformin. 
Adding canagliflozin to insulin will be cost-effective compared with placebo. 
Canagliflozin is a cost-effective alternative to sulfonylurea in mono therapy.
PDB73
eConomiC evaluation of BlooD gluCose Point–of–Care testing in the 
intensive Care unit
SteutenL.M.G. 1, Kip M.2, Hooijdonk R.3, Monteban H.4, Spronk P.5, Schultz M.3
1University of Twente, Enschede, The Netherlands, 2PANAXEA bv, Enschede, The Netherlands, 
3Amsterdam Medical Center/University of Amsterdam, The Netherlands, 4Monteban Value 
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Objectives: Point–of–care testing of blood glucose (BG–POCT) is essential for safe 
insulin infusion in critically ill patients. Costs associated with BG–POCT are consid-
ered substantial, especially when more frequent monitoring is needed as with strict 
glucose control aiming for lower BG–levels. The objective of this study is to estimate 
the incremental cost-effectiveness of a strict BG-POCT guideline versus a loose 
guideline, from a hospital perspective. MethOds: This is a secondary analysis of 
a guideline implementation project aiming for normal BG–levels in three intensive 
care units in The Netherlands[1]. A Markov model including health states ‘target 
glucose’, ‘hyperglycemia’, ‘hypoglycemia’, and hospital death was developed to com-
pare expected costs, number of patients within target and number of life years 
saved before and after guideline implementation. Results: The analysis included 
1.321 and 2.175 patients 12 and 24 months before and after implementation of the 
guideline, respectively. The number of BG-POCT increased from 4.2 [2.6 – 6.7] to 8.7 
[4.1 – 11.2] per patient per day. Costs for BG–POCT increased with 72%. When taking 
total hospital costs and clinical effects into account, implementation of the strict 
glycemic control guideline reduces hospital costs with € 134 during total inpatient 
stay, as patients spend less time in hypo/hyperglycemic events and had shorter stays 
in ICU and hospital (–0.5 and –1.1 day, respectively). This translates into expected 
cost savings of € 13 per additional patient in target glucose and € 10 per additional 
life year saved. The model outcomes are most sensitive to changes in ICU length of 
stay. cOnclusiOns: This health–economic analysis shows that additional costs 
of BG–POCT with implementation of a strict glucose control guideline are offset 
against savings generated by reduced hypo/hyperglycemic events and length of stay 
in ICU and hospital. [1] Schultz, M.J., et al. Minerva Anestesiol, 2012. 78(9): p. 982-95.
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Cost-effeCtiveness of switChing to BiPhasiC insulin asPart from 
human Premix insulin in PeoPle with tyPe 2 DiaBetes in China
Xiao J.1, Bian X.2, Zhang Y.3, Yang L.4
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Objectives: To evaluate long-term cost-effectiveness of switching from human 
premix insulin to biphasic insulin aspart (BIAsp 30) in people with type 2 diabetes 
mellitus (T2DM) in China. MethOds: The previously published and validated IMS 
Core Diabetes Model was used to project life expectancy, quality-adjusted life years 
(QALYs) and total direct medical costs over 30 years from a societal perspective. 
Patient characteristics and treatment effects were obtained from Chinese subgroup 
(n= 1191) in the A1chieve® observational study. After treatment with BIAsp 30 over 24 
weeks, patients’ HbA1c decreased by 1.6%, rate of major and minor hypoglycaemia 
decreased by 0.51 and 4.32 events per patient-year respectively. Treatment costs 
were based on insulin doses (35.8 IU daily for human premix insulin and 36.1 IU for 
BIAsp 30) and market retail prices in China. Management (concomitant medications, 
screening programmes, etc) and complication costs were obtained from Chinese 
published data in 2011 and adjusted to the price level of 2012 with the consumer 
price index. Costs and life years were discounted at 3% annually. One-way sensitiv-
ity analysis was performed. Results: Switching to BIAsp 30 from human premix 
insulin was projected to reduce incidence of most diabetes-related complications, 
increase life expectancy by 0.732 years (13.457 vs 12.725 ) and improve quality-
adjusted life years by 1.032 QALYs (9.487 vs 8.455) per patient. Although treatment 
and management costs increased by Chinese Yuan (CNY) 14,712 (52,329 vs. 37,617) 
and 1,857 (39,821vs. 37,964) respectively, complication costs reduced by CNY 96,198 
(104,752 vs. 200,950); switching to BIAsp 30 from human premix insulin was asso-
ciated with reduced total direct medical cost of CNY 79,628 (196,902 vs. 276,530). 
Sensitivity analyses demonstrated robustness of the results. cOnclusiOns: 
Switching to BIAsp 30 from human premix insulin was associated with improve-
ments in life expectancy and QALYs, and was a cost-saving treatment strategy for 
people with T2DM in China.
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Cost-effeCtiveness of saxagliPtin anD linagliPtin in ComBination 
with metformin for tyPe ii DiaBetes: a DeCision-tree analysis moDel
Sawant R.V.1, Sansgiry S.S.2
1University Of Houston, Houston, TX, USA, 2University of Houston, Houston, TX, USA
glycemic control, leading to a reduced incidence of diabetes-related complications, 
including renal disease, cardiovascular disease, ophthalmic and diabetic foot com-
plications. Liraglutide was associated with increased direct costs (EUR 56,628 versus 
EUR 52,450), driven by the acquisition cost of liraglutide. However, this was partially 
offset by the reduced cost of treating diabetes-related complications. Based on these 
estimates, liraglutide was associated with an incremental cost-effectiveness ratio 
of EUR 10,436 per QALY gained versus sitagliptin. cOnclusiOns: Liraglutide 1.8mg 
was projected to improve clinical outcomes over sitagliptin as a result of reduced 
incidence of diabetes-related complications. Liraglutide is likely to be cost-effective 
from a health care payer perspective in Spain.
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Objectives: Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as exena-
tide once weekly (EQW) and liraglutide (LIRA), are FDA-approved as treatment 
for type 2 diabetes mellitus (T2DM). Head-to-head studies and meta-analyses of 
these agents have reached different conclusions about their relative effective-
ness. MethOds: We developed a decision-analytic model to evaluate the likely 
incremental cost-effectiveness of EQW versus LIRA 1.8 mg in T2DM patients, with 
effectiveness measured as reduction in glycated hemoglobin (HbA1c). The model 
structure tracks change in HbA1c and direct medical expenditure (drug, needle, 
adverse events [AEs]) over a 26-week time horizon, and allows patients to discon-
tinue treatment due to AEs (nausea, diarrhea, vomiting, constipation, dyspepsia) 
after 1 or 3 months of therapy. Patients discontinuing treatment are assumed to 
return to their baseline HbA1c. We compared the outcomes (cost per 1% and 0.2% 
reduction in HbA1c) of models populated with clinical data from a head-to-head 
26-week randomized, controlled trial (DURATION-6) and a meta-analysis conducted 
by Scott and colleagues (2012). Drug costs and other utilization costs were based 
on wholesale acquisition costs and published sources. Results: For the base 
case, the projected total 6-month cost of EQW versus LIRA was $2,444 and $3,054, 
respectively. Using data from DURATION-6 and meta-analysis, compared with EQW, 
LIRA had a projected incremental cost per 1% reduction in HbA1c (ICER) of $3,262 
and $18,578 over a 6-month time horizon, respectively. Compared with EQW, the 
projected 6-month cost per 0.2% reduction in HbA1c for LIRA was $652 and $3,716 
based on data from DURATION-6 and meta-analysis, respectively. cOnclusiOns: 
The projected cost per 1% reduction in HbA1c was lower with EQW than liraglutide 
1.8 mg at 6 months. The difference in projected cost per HbA1c reduction varies 
significantly depending on the trial-based data sources used. Real-world data are 
needed to resolve the current uncertainties.
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men with hyPogonaDotroPiC hyPogonaDism in the Context of an 
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Objectives: To evaluate the efficiency, in terms of incremental cost-effectiveness 
ratios (ICER), of human chorionic gonadotropin (hCG) and human gonadotropins, 
drugs used for male infertility due to hormonal disorder hypogonadotropic hypo-
gonadism (HH), whose female partner has or doesn’t have infertility problems, in 
the context of an assisted reproduction program. MethOds: Two different decision 
trees were developed to assess ICER of hCG and human gonadotropins. Firstly, hCG 
was compared to no treatment; secondly, human gonadotropins in combination 
with hCG were compared to hCG used alone. Effectiveness was measured as preg-
nancy and spermatogenesis respectively. Data were obtained from clinical studies, 
as well as efficacy of medical procedures. The proportion of couples, who needed 
fertility procedures, was determined according to experts’ opinion. A ministry of 
health perspective was taken. Costs of medications were based on acquisition costs 
in 2012 Canadian dollars. Costs of medical procedures, as intrauterine insemination 
(IUI), in vitro fertilisation (IVF) and intra cytoplasmic sperm injection (ICSI) were 
based on 2012 fees of Québec’s physicians. The time horizons adopted were based 
on the durations of drug treatment in clinical studies. Results: The use of hCG 
in comparison with no treatment is cost-effective with an ICER of 20,915$CAN per 
man with HH for whom the partner got pregnant. Determinist sensitivity analyses 
showed that the ratio is more sensitive to the probability to use IVF or ICSI. In the 
second comparison, treatment with human gonadotropins is cost-effective with 
an ICER of 25,076$CAN per man that obtained spermatogenesis. Drug dosage is the 
element for which the ICER is more sensitive in the univariate determinist sensitiv-
ity analyses. cOnclusiOns: Human gonadotropins and hCG are cost-effective for 
the treatment of men with HH. They can be reimbursed in the drug program for this 
indication with some restrictions about the duration of treatment.
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Objectives: To evaluate the cost-effectiveness of canagliflozin in dual therapy as 
add-on to metformin compared to sitagliptin and glimepiride, as add on to insulin 
(plus metformin) and in mono therapy compared to sulfonylurea in the Swedish 
setting from a societal perspective. MethOds: The IMS CORE Diabetes Model was 
used to evaluate the cost-effectiveness of canagliflozin (using a weighted average 
of 80/20 for the 100 mg and 300 mg dosage respectively) versus the aforementioned 
